SNAP-8

SNAP-8 is a linear 8-residue peptide with an N-terminal acetylation modification that confers resistance to aminopeptidase cleavage. The molecule's sequence corresponds to the N-terminal segment of human SNAP-25, providing the structural basis for its interaction profile in the literature: competitive binding with native SNAP-25 in SNARE-complex assembly, downstream effects on vesicle-fusion biochemistry studied in cell-free reconstituted systems and cell-culture neuromuscular-junction models. Pharmacokinetic descriptors documented in published animal-model investigations include rapid plasma clearance under standard parenteral paradigms — a property characteristic of small unmodified-but-acetylated peptide fragments. Interaction profile in the literature centers on SNARE-complex disruption studies, neurotransmitter-release biochemistry research, and comparative work alongside related SNAP-25-mimic peptides. All activity descriptors here are framed as documented in published research. Structural confirmation is established by mass spectrometry and HPLC-validated purity on each Certificate of Analysis.

Experimental domains documented in the published literature include SNARE-complex assembly and disruption assays in cell-free reconstituted systems, vesicle-fusion biochemistry research, neuromuscular-junction studies in cell-culture and tissue-preparation models, structure-activity work probing the role of the N-terminal acetylation in proteolytic stability, comparative work alongside related SNAP-25-mimic peptides, and screening assays for SNARE-pathway-active short peptide research. Investigators have also characterized SNAP-8 in cosmetic-chemistry research literature and in skin-cell-culture model systems. Use in laboratory research extends to mechanism-elucidation paradigms where the octapeptide serves as a defined SNAP-25-mimic reference. The reference standard is supplied for these and equivalent in-vitro and analytical experimental contexts only, with no associated guidance for human, cosmetic-product, clinical, or veterinary application. Researchers should consult primary literature for context-specific protocols.

Each lot is characterized by reverse-phase HPLC for chromatographic purity and by mass spectrometry for molecular-ion confirmation against the C42H72N16O15S empirical formula. Purity is reported as an HPLC-area percentage on the Certificate of Analysis distributed with every lot, alongside the molecular-weight match within instrument tolerance. The N-terminal acetylation modification is confirmed by tandem mass spectrometry when included in the lot's release specification. Peptide content where applicable is determined by amino-acid analysis or nitrogen-content assay following the analytical method specified on the COA. Residual solvent and water content are reported categorically when these parameters are part of the lot's release specification. The COA records the lot identifier, manufacturing date, and analytical method versions used. Researchers requiring batch-level analytical detail should reference the COA distributed with the supplied material.

For laboratory storage, the lyophilized reference standard should be held at −20°C in its sealed, light-protected container until ready for analytical use. Allow vials to equilibrate to ambient temperature before opening to avoid moisture condensation on the lyophile. Reconstitution for in-vitro experimental use is typically performed in bacteriostatic water or a researcher-selected buffer compatible with the downstream assay; once reconstituted, store the working solution at 2–8°C and characterize stability in the relevant buffer prior to extended storage. Avoid repeated freeze-thaw cycles of reconstituted material — single-use aliquots are preferred for experiments where peptide integrity is assay-critical. These handling parameters reflect general best-practice for lyophilized peptide reference standards and do not constitute preparation guidance for human, cosmetic, or veterinary application.